COMMON MAPS
Map version new-york activity top-down
Main site Contact
Menu
↑ parent activity group ·
research dossier

Ludwig Institute for Cancer Research Ltd
New York, NY · EIN 237121131 · Form 990 · FY2024 · Very Large (>$50M) · ludwigcancerresearch.org
revenue
$63.0M
expenses
$64.3M
net assets
$1.1M
employees
31
program ratio
84%
mission · from form 990

The Ludwig Institute for Cancer Research Ltd is a global non-profit institute committed to improving the under- standing & control of cancer through laboratory and clinical research.

profile · synthesized from sources

The Ludwig Institute for Cancer Research Ltd is a global nonprofit dedicated to advancing the understanding and control of cancer through laboratory and clinical research. Its scientists investigate cancer biology, tumor immunology, genomics, and the tumor microenvironment to develop new diagnostics and therapies. The institute operates through a network of research centers worldwide, fostering collaboration between basic scientists and clinicians.

irs program accomplishments · form 990 part iii · fy2023

What they reported doing

  1. #1 primary $122K
    Clinical research - see schedule O
named programs · 4 · from sources

What they call their work

Early Detection of Cancer
Research led by Ludwig Johns Hopkins scientists to develop non-invasive methods for detecting cancer at earlier stages, improving curability.
Pharmacogenomics Research
Development of isogenic cell lines to study drug interactions with the genetic diversity of tumors, identify drug resistance mechanisms, and discover novel therapeutic targets.
Tumor Atlas Project
A collaborative effort among five Ludwig-affiliated labs using advanced microscopy, genetic, and computational tools to map interactions between tumor and immune cells in the tumor microenvironment to improve diagnosis and therapy.
Tumor Microenvironment Research
Studies focused on how noncancerous cells support tumor growth and immune evasion, with the goal of identifying new therapeutic targets.
activities · 5 groups

What they do

  • Biomedical Research and Innovation 3 activities
    • Cancer genomics and genome-wide research
      Conducts genome-wide analyses to understand the role of DNA sequence variations, disrupted DNA repair mechanisms, and epigenetic changes in cancer initiation, evolution, and metastasis. Also conducts large-scale research to identify functional elements of the human genome using advanced technologies.
    • Early detection and prevention research
      Conducts research on the early, non-invasive detection of cancer, particularly gastrointestinal, esophageal, and gastric cancers, and estimates colon cancer risk. Also investigates diet-based prevention strategies in partnership with the Conrad N. Hilton Foundation.
    • Immunotherapy development and clinical translation
      Developed the first known naturally occurring tumor antigens and provided foundational evidence for tumor immune escape. Brought first-generation immunotherapies to the clinic and has developed candidate immunotherapies, one of which is entering clinical trials in collaboration with Pfizer.
  • Cancer Research Funding 2 activities
    • Drug resistance and target discovery using isogenic cell lines
      Developed genetically uniform (isogenic) cell lines to study how tumor genetics influence drug response, analyze mechanisms of drug resistance, and identify candidate drug targets in major cancers.
    • Tumor microenvironment and tumor biology research
      Studies interactions between tumor and immune cells within the tumor microenvironment using advanced microscopy, genetic, and computational tools. Also investigates intracellular signaling networks, metabolic adaptations, genomic changes, and biochemical alterations in cancer cells to understand tumor growth, metastasis, and therapy resistance.
  • Patient and Researcher Conferences 1 activity
    • Dissemination of cancer research findings
      Shares insights from decades of research in genomics, molecular biology, and cancer mechanics through public webinars, including on topics such as early cancer detection.
  • Neurological Disorder Research & Rehabilitation 1 activity
    • Glioblastoma research
      Conducts multi-year joint investigations into glioblastoma to understand its biology and mechanisms of therapy resistance.
  • Research Facility Management 1 activity
    • International research operations and scientific collaboration
      Operates research branches in multiple global locations including Baltimore, Boston, Brussels, Chicago, Lausanne, New York, Oxford, Princeton, Stanford, and Zurich, enabling broad scientific collaboration across focus areas.
financials · form 990 · fy2024
revenue
Total revenue$63.04M
Contributions & grants$61.02M97%
Program service revenue$00%
Investment income$43K0%
Other revenue$1.98M
expenses
Total expenses$64.27M
Program expenses84%
Admin / overhead16%
Fundraising0%
Salaries & benefits$9.94M
Grants paid out$0
Largest expense lineCompensation
balance sheet
Total assets$15.65M
Cash$2.89M
Investments$5.28M
Liabilities$14.57M
Net assets$1.08M
Liquid reserves1.5 mo
3 years on record · 2020–2024 · YoY revenue -13.5%
leadership · form 990 part vii · fy2024

Who runs it

paid leadership · 20
NameTitleHours/wkCompensation
Xing Chen Director (From 7/24) 1 $1.20M
Dr Chi Van Dang Dir, Sci. Dir, CEO (From 7/24) 50 $1.18M
Dr Jonathan Skipper President (From 7/24) 45 $863K
Edward A McDermott Jr Dir, Board Chair (From 7/24) 44 $671K
Thomas Baenninger Chief Financial Officer 40 $663K
Yang Shi Group Leader 10 $531K
George Coukos Branch Director 40 $502K
Patrice Morin Deputy Scient. Dir. 45 $481K
Xin Lu Branch Director 10 $463K
Michael Macaranas BRANCH ADMINISTRATOR(END 4/24) 40 $410K
Alexander Borissov SEC. TO BOARD, INTERNAL AUDIT 37 $364K
Richard White Group Leader 10 $350K
Gerd Ritter TECHNOLOGY DEVELOPMENT MANAGER 40 $334K
John L Notter Dir, Board Chair (End 6/24) 8 $115K
Jedd Wolchok DIRECTOR 2 $96K
John D Gordan III Director 2 $96K
Alexandra Johnson Director 2 $41K
Dr Nancy Ellen Davidson Director 2 $41K
Judge Barbara S Jones Director 2 $41K
Nicolas Killen Director 2 $41K
relationships · 14

Who they work with

  • Conrad N. Hilton Foundation Partner — Collaborates on a research program focused on diet-based prevention and early, non-invasive detection of gastrointestinal cancers.
  • Harvard University Partner — Hosts Ludwig Cancer Research scientists at its Boston campus.
  • Johns Hopkins Partner — Co-directs Ludwig research activities with Ken Kinzler and Bert Vogelstein
  • Ludwig Harvard Partner — Collaborates on the Ludwig Tumor Atlas Project and conducts research on tumor microenvironment normalization.
  • Ludwig Lausanne Partner — Conducts research on myeloid cells in the tumor microenvironment and therapeutic targeting strategies.
  • Ludwig MIT Partner — Participates in the Ludwig Tumor Atlas Project through collaborative research efforts.
  • Ludwig Oxford Partner — Researches hypoxia signaling pathways and their implications for cancer.
  • Massachusetts Institute of Technology Partner — Hosts Ludwig Cancer Research scientists at its Boston campus.
  • Memorial Sloan Kettering Cancer Center Partner — Hosts Ludwig Cancer Research scientists at its New York location.
  • Oxford Partner — Hosted Ludwig researcher Sebastian Nijman
  • Pfizer Partner — Collaborating with Ludwig on the clinical development of a candidate immunotherapy.
  • Pfizer Partner — Collaborating with Ludwig researchers to advance a candidate immunotherapy into clinical trials.
  • San Diego Partner — Hosts Ludwig researchers Bing Ren, Web Cavenee, Frank Furnari and Paul Mischel
  • Weill Cornell Medicine Partner — Hosts Ludwig Cancer Research scientists at its New York location.
strategies · 4

How they approach the work

Named approaches extracted from this org’s sources. Where others share an approach, follow it to see the full set of orgs running it.

  • Decentralized Research Network Model
    methodology: decentralized_research_network
    By conducting research through a geographically distributed network of laboratories, the organization leverages diverse scientific expertise and institutional collaborations to accelerate discovery, because decentralized structures enhance access to specialized knowledge and experimental capacity.
  • Multidisciplinary Integration in Cancer Research
    methodology: multidisciplinary_integration_in_cancer_research
    By combining subdisciplines such as cancer genomics, tumor immunology, and molecular imaging, the organization addresses the complexity of tumor biology, because integrated expertise enables a more comprehensive understanding of cancer mechanisms and therapy resistance.
  • Thematic Research Focus
    methodology: thematic_research_focus
    By concentrating on specific thematic areas of cancer biology, the organization deepens mechanistic understanding and enables targeted therapeutic development, because focused inquiry supports sustained progress in complex domains like tumor microenvironment dynamics and immunotherapy.
  • Translational Research Pipeline
    methodology: translational_research
    By integrating basic scientific discoveries with clinical applications, the organization advances cancer diagnostics, therapies, and preventive interventions, because bridging laboratory and clinical research accelerates the development of effective treatments.